Analyst consensus rating
Anika Therapeutics Analyst Rating: none
Direct answer
Anika Therapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.00.
Forecast evidence checked September 4, 2026.
Get free Anika Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $21.00
- Average price target
- $21.00
- High price target
- $21.00
- Low price target
- $21.00
- Low target gap
- 0%
- Target upside
- 0%
- High target gap
- 0%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Anika Therapeutics?
Anika Therapeutics has a verified none consensus. The same dataset has an average price target of $21.00.
How far are Anika Therapeutics's low and high targets from the recorded price?
The low target implies 0%, while the high target implies 0%.
How many analysts are included in Anika Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Anika Therapeutics's target upside or downside calculated?
The average target of $21.00 is divided by the recorded price of $21.00, then one is subtracted to produce 0%. This does not guarantee a future return.
When was Anika Therapeutics's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.